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Introduction:
The objective of this randomized controlled trial (RCT) has been to evaluate the efficacy and tolerability of the alpha-1 adrenergic antagonist prazosin compared to placebo for combat stressrelated nightmares, sleep disturbance, and global function in combat trauma-exposed Service Members who are in garrison at Joint Base Lewis McChord (JBLM). The secondary objectives of this trial are to assess the efficacy of prazosin for reducing total PTSD symptoms, reducing symptoms of depression and improving quality of life.
Active duty soldiers who have experienced combat in OIF/OEF/OND and who have persistent combat stress-related nightmares and sleep disturbance in the context of combat trauma PTSD have been enrolled in the study. Participants undergo a flexible dose titration period followed by optimal dose treatment for a total of 15 weeks including the titration period. Primary and secondary outcome measures assess nightmares, sleep disturbance, PTSD severity by total CAPS score, depression, global function, and quality of life and are administered every four weeks (weeks 7, 11 and 15).
Body:
We have successfully launched and brought to a halfway point preplanned interim analysis what, to our knowledge, is the first ever medication randomized controlled trial for PTSD (or any other behavioral disorder) performed in US active duty combat experienced Service Members. Our active outreach approach to recruitment across JBLM has successfully attracted volunteers for research participation, and also has provided support to the Psychiatry Service mission at Madigan Army Medical Center (MAMC) and JBLM.
Key Research Accomplishments
 We performed a planned "halfway" interim analysis on the first 67 randomized subjects. 54 had at least one full behavioral outcome (the evaluable sample) and 49 completed the entire 15-week trial. An Intent to treat linear mixed effects models analysis utilizing data from all randomized subjects has been performed.
Reportable Outcomes
Prazosin was significantly superior to placebo for all three primary outcome measures. CAPS B2 nightmare score decrease from baseline to end point was 3.1 ± 0.3 (mean ± SE) in the prazosin group vs. 1.2 ± 0.3 in the placebo group (difference in change from baseline p < 0.001, 95%, CI for difference in change from baseline [1.0, 2.8]). PSQI decrease from baseline to endpoint was 5.6 ± 0.7 in the prazosin group vs. 2.8 ± 0.6 in the placebo group (difference in change from baseline p=0.004, 95% CI [0.9, 4.6]) adjusted per cent CGIC responders ("markedly" or "moderately" improved for prazosin subjects was 64% (95% CI • Hypothesis: Prazosin is more effective than placebo for PTSD nighttime symptoms, function, and overall PTSD in active duty soldiers returned from combat deployments to OEF/OIF/OND.
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Sleep Quality Index (PSQI), Clinical Global Impression of Change (CGI) anchored to function, and 17 item CAPS total score.
• Military Relevance: PTSD is a common cause of distress and disability in service members and Veterans.. • Prazosin is a generically available (inexpensive) alpha-1 adrenoreceptor antagonist that easily enters the brain and reduces excessive norarenergicmediated arousal.
• 
METHODS
• Soldiers randomized to prazosin or placebo for 15 weeks (6 week titration, 9 week maintenance dose). Outcome ratings at weeks 7, 11, and 15. 
RESULTS
• 56 of 67 subjects completed at least one rating period, and 46 the entire 15-week study. Data analyzed with linear mixed effects models using data from all 67 randomized subjects.
• Average doses achieved in male soldiers:
Prazosin (mg) Placebo (mg)* 4.0 ± 1.4 midmorning/15.6 ± 6.0 bedtime 4.8 ± 0.8 midmorning/18.8 ± 3.3 bedtime *placebo > prazosin, p < 0.05
• Prazosin significantly superior for CAPS hyperarousal cluster and numerically superior for depression ratings (HAM-D, PHQ-9). No drug effect on blood pressure.
